| 1 |
Robert DiCosimo |
E.I. Du Pont De Nemours And |
5 |
| 2 |
John Christopher Sworen |
The Chemours Company Fc |
4 |
| 3 |
Mario W. Chen |
E.I. Du Pont De Nemours And |
3 |
| #4 |
Kai-Volker Schubert |
E.I. Du Pont De Nemours And |
2 |
| #4 |
Wenqing Yao |
Incyte |
2 |
| #4 |
Thomas Durig |
Hercules |
2 |
| #4 |
William D. Budinger |
Rodel Holdings |
2 |
| #4 |
Patrick Lam |
Bristol-Myers Squibb |
2 |
| #4 |
Paul F. Jackson |
Guilford Pharmaceuticals |
2 |
| #10 |
Kate Marritt Lusvardi |
Solenis Technologies |
1 |
| #10 |
H. Samuelson |
E.I. Du Pont De Nemours And |
1 |
| #10 |
Toshikazu Kobayashi |
E.I. Du Pont De Nemours And |
1 |
| #10 |
Paul Douglas Brothers |
E.I. Du Pont De Nemours And |
1 |
| #10 |
Jan J. Lerou |
E.I. Du Pont De Nemours And |
1 |
| #10 |
David S. Milowicki |
Unisys |
1 |
| #10 |
Ke PAN |
Jiangsu Yahong Meditech Co. |
1 |
| #10 |
Craig Robert Gochanour |
E.I. Du Pont De Nemours And |
1 |
| #10 |
Eugene Michael McCarron, III |
E.I. Du Pont De Nemours And |
1 |
| #10 |
Patrick Y. S. Lam |
Bristol-Myers Squibb |
1 |
| #10 |
Steve Beck |
Microsoft |
1 |
| #10 |
Tianyi Liao |
Invista North America S.A.R.L. |
1 |